Patents by Inventor Frank Himmelsbach

Frank Himmelsbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ß-d-glucopyranos-1-yl)-benzene, L-proline and water
    Patent number: 11629161
    Abstract: Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene L-proline monohydrate.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: April 18, 2023
    Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
  • USES OF DPP IV INHIBITORS
    Publication number: 20220184088
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: February 28, 2022
    Publication date: June 16, 2022
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • Uses of DPP IV inhibitors
    Patent number: 11291668
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: April 5, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER
    Publication number: 20220081461
    Abstract: Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene L-proline monohydrate.
    Type: Application
    Filed: November 30, 2021
    Publication date: March 17, 2022
    Inventors: Matthias ECKHARDT, Monika BRINK, Frank HIMMELSBACH, Stefan SAHLI, Chutian SHU, Xiao-Jun WANG, Beat Theodor WEBER, Bing-Shiou YANG
  • Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(?-D-glucopyranos-1-yl)-benzene, L-proline and water
    Patent number: 11225500
    Abstract: The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: January 18, 2022
    Inventors: Matthias Eckhardt, Monika Brink, Frank Himmelsbach, Stefan Sahli, Chutian Shu, Xiao-Jun Wang, Beat Theodor Weber, Bing-Shiou Yang
  • SYNTHESIS OF 1:1:1 CO-CRYSTAL OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(ß-D-GLUCOPYRANOS-1-YL)-BENZENE, L-PROLINE AND WATER
    Publication number: 20210139520
    Abstract: The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.
    Type: Application
    Filed: December 17, 2018
    Publication date: May 13, 2021
    Inventors: Matthias ECKHARDT, Monika BRINK, Frank HIMMELSBACH, Stefan SAHLI, Chutian SHU, Xiao-Jun WANG, Beat Theodor WEBER, Bing-Shiou YANG
  • Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors
    Patent number: 10730850
    Abstract: The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (with the proviso that at least one of X1 and X2 is N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: August 4, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Andreas Blum, Stefan Peters
  • USES OF DPP IV INHIBITORS
    Publication number: 20200222411
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: March 25, 2020
    Publication date: July 16, 2020
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • Uses of DPP IV inhibitors
    Patent number: 10668074
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 2, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
    Patent number: 10442795
    Abstract: The present invention relates to processes for preparing the compounds of general formula I, wherein the groups R1 and R3 are defined according to claim 1. Furthermore this inventions relates to intermediates obtained in these processes.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: October 15, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Eckhardt, Frank Himmelsbach, Xiao-Jun Wang, Wenjun Tang, Xiufeng Sun, Li Zhang, Dhileepkumar Krishnamurthy, Christopher Hugh Senanayake, Zhengxu Han
  • 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors
    Patent number: 10336729
    Abstract: The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: July 2, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Andreas Blum, Stefan Peters
  • PYRIDINYLMETHYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS
    Publication number: 20190084959
    Abstract: The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (whith the proviso that at least one of X1 and X2 is N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: March 3, 2016
    Publication date: March 21, 2019
    Inventors: Frank HIMMELSBACH, Andreas BLUM, Stefan PETERS
  • 4-CYANO-BENZYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS
    Publication number: 20190077790
    Abstract: The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Application
    Filed: April 3, 2016
    Publication date: March 14, 2019
    Inventors: Frank HIMMELSBACH, Andreas BLUM, Stefan PETERS
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent number: 10202383
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: June 14, 2018
    Date of Patent: February 12, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier
  • USES OF DPP IV INHIBITORS
    Publication number: 20180353513
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 13, 2018
    Inventors: Klaus DUGI, Frank HIMMELSBACH, Michael MARK
  • 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
    Publication number: 20180291025
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Application
    Filed: June 14, 2018
    Publication date: October 11, 2018
    Inventors: Frank HIMMELSBACH, Elke LANGKOPF, Matthias ECKHARDT, Roland MAIER
  • Uses of DPP IV inhibitors
    Patent number: 10080754
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 25, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Azabenzimidazole derivatives
    Patent number: 10053471
    Abstract: The present invention relates to compounds of general formula (I), wherein R1, R2, R3, A1, A2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: August 21, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Elke Langkopf
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent number: 10023574
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 17, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Roland Maier
  • N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof
    Patent number: 9926308
    Abstract: Compounds of formula I wherein R1, LP, n, HetAr1, and HetAr2 are as defined herein, and salts thereof, pharmaceutical compositions containing these compounds, and methods for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119, such as diabetes, dislipidemia, or obesity, by administering to a patient in need thereof these compounds or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: March 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Bernd Nosse, Matthias Eckhardt, Frank Himmelsbach, Elke Langkopf, Neil J. Ashweek, Nicole Harriott